Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | PEPD | P12955 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449168 | 0.78 | PIK3CD (0.50) | HRH3HRH4PEPDKDM4EPIK3CD | |
| SCHEMBL14444864 | 0.78 | PIK3CD (0.50) | HRH3HRH4PEPDKDM4EPIK3CD | |
| SCHEMBL23158454 | 0.78 | PIK3CD (0.50) | HRH3HRH4PEPDKDM4EPIK3CD | |
| SCHEMBL27282853 | 0.78 | PIK3CD (0.50) | HRH3HRH4PEPDKDM4EPIK3CD | |
| SCHEMBL19982004 | 0.77 | KDM4E (0.58) | HRH3KDM4ELMNARAB9A | |
| SCHEMBL19972739 | 0.75 | SIGMAR1 (0.41) | HRH3LMNA | |
| SCHEMBL19981797 | 0.75 | SIGMAR1 (0.41) | HRH3LMNA | |
| SCHEMBL21294392 | 0.75 | SIGMAR1 (0.41) | HRH3LMNA | |
| SCHEMBL17828064 | 0.71 | HRH3 (0.36) | HRH3HRH4KDM4EPIK3CDSMN1; SMN2 | |
| SCHEMBL19981827 | 0.71 | KDM4E (0.33) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | RESEARCH TRIANGLE INSTITUTE (NC) | 2022-04-05 | — | — | US | disclosed |
| EP-3512832-B1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RES TRIANGLE INST (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | RESEARCH TRIANGLE INSTITUTE (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2018053222-A1 | TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS | RESEARCH TRAINGLE INSTITUTE (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11292783-B2 | Substituted 1,2,3,4-tetrahydroisoquinolines as kappa opioid antagonists | OPRK1, OPRD1, OPRM1 | HRH3 933/4885HRH4 930/4885PEPD 4386/4885 |
| US-20190263781-A1 | Tetrahydroisoquinoline Kappa Opioid Antagonists | OPRK1, OPRD1, OPRM1 | HRH3 869/4885HRH4 874/4885PEPD 4213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.